Sign up to save your podcasts
Or
Share Inside the Issue: Integrating Bispecific Antibodies into the Management of Multiple Myeloma — Patient Selection and Toxicity Management
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Inside the Issue: Integrating Bispecific Antibodies into the Management of Multiple Myeloma — Patient Selection and Toxicity Management
Dr Hans Lee from The University of Texas MD Anderson Cancer Center in Houston, Texas, and Dr Saad Zafar Usmani from Memorial Sloan Kettering Cancer Center in New York, New York, discuss approved and novel bispecific antibodies and their current and potential roles in the treatment of multiple myeloma.
View all episodes
By Dr. Neil Love
4.4
6969 ratings
Dr Hans Lee from The University of Texas MD Anderson Cancer Center in Houston, Texas, and Dr Saad Zafar Usmani from Memorial Sloan Kettering Cancer Center in New York, New York, discuss approved and novel bispecific antibodies and their current and potential roles in the treatment of multiple myeloma.
More shows like Hematologic Oncology Update
View all
JAMA Editors' Summary
130 Listeners
Gastrointestinal Cancer Update
17 Listeners
Lung Cancer Update
32 Listeners
Prostate Cancer Update
15 Listeners
Breast Cancer Update
66 Listeners
Gynecologic Oncology Update
11 Listeners
Dermatologic Oncology Update
0 Listeners
NEJM This Week
325 Listeners
Research To Practice | Oncology Videos
113 Listeners
The Hematologist
26 Listeners
JAMA Clinical Reviews
492 Listeners
Annals On Call Podcast
185 Listeners
Blood Podcast
51 Listeners
Oncology Today with Dr Neil Love
52 Listeners
WolverHeme Happy Hour
29 Listeners
Two Onc Docs
169 Listeners
Blood Cancer Talks
48 Listeners